Table of Contents
ISRN Pharmacology
Volume 2011, Article ID 480291, 4 pages
Review Article

Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review

1Medical Writing Group, Accenture Pharmaceutical Services, Karnataka, Bangalore 560072, India
2Allied Health Sciences, Sikkim Manipal University, Karnataka, Bangalore 560008, India
3Department of Pharmaceutics, Gautham College of Pharmacy, Karnataka, Bangalore 560032, India
4Department of Pharmaceutical Chemistry, Pushpagiri College of Pharmacy, Thiruvalla, Kerala 689101, India

Received 4 February 2011; Accepted 21 March 2011

Academic Editor: J.-A. Mico

Copyright © 2011 Sam T. Mathew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In the clinical management of arthritis, the choice of nonsteroidal anti inflammatory drug (NSAID) remains confusing and controversial. A common practice on the choice of NSAID in clinical management of arthritis is the risk benefit ratio. The main objective of this review is to addresses the main arguments for the pharmacological and clinical use of COX-2 inhibitors in relation to nonselective NSAIDs for the clinical management of arthritis. This review concluded that, both NSAIDs and COX-2 inhibitors are equally effective and are associated with increased risk of GI, renal, and CV, adverse effects. Complete understanding of the patient's comorbid conditions and concomitant medications, coupled with precise monitoring during the treatment, may help to decrease the threat of adverse effects induced by nonselective NSAIDs and selective COX-2 inhibitors.